IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice

Am J Respir Crit Care Med. 1999 Dec;160(6):2040-7. doi: 10.1164/ajrccm.160.6.9901043.

Abstract

Cystic fibrosis (CF) lung disease is characterized by an excessive inflammatory response associated with chronic Pseudomonas aeruginosa endobronchial infection. Compared with bronchoalveolar lavage fluid from healthy subjects, lavage fluid from patients with CF contains elevated proinflammatory cytokines but negligible amounts of the anti-inflammatory cytokine interleukin-10 (IL-10). We sought to determine whether IL-10 deficiency results in increased local and systemic morbidity in mice with chronic endobronchial infection with P. aeruginosa embedded in agar beads and to determine if exogenous IL-10 might reduce these effects. Infected IL-10 knockout mice had more severe weight loss (p = 0.04) and increased area of lung inflammation (28 +/- 4 versus 10 +/- 2%, p < 0.002) but no alterations in bacterial burden compared with wild-type mice. Infected CD-1 mice treated with IL-10 had improved survival (p = 0. 035), less severe weight loss (p < 0.005), fewer bronchoalveolar lavage neutrophils (3 x 10(5)/ml versus 5 x 10(6)/ml, p < 0.02), and decreased area of lung inflammation (11 +/- 2 versus 35 +/- 7%, p < 0.01) but no alterations in bacterial burden compared with placebo-treated mice. These data suggest that IL-10 is an important regulator of the inflammatory response to P. aeruginosa endobronchial infection and that further investigation into the use of IL-10 in CF is warranted.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Bronchoalveolar Lavage Fluid / chemistry
  • Bronchoalveolar Lavage Fluid / cytology
  • Chronic Disease
  • Cystic Fibrosis / complications
  • Inflammation
  • Interleukin-10 / therapeutic use*
  • Lung / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred Strains
  • Mice, Knockout
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / mortality
  • Pseudomonas Infections / pathology*
  • Respiratory Tract Infections / complications
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / mortality
  • Respiratory Tract Infections / pathology*
  • Survival Rate
  • Weight Loss

Substances

  • Interleukin-10